According to a new report published by UnivDatos Markets Insights, the liquid biopsy in cancer diagnostic market was valued at USD 7.5 billion in 2021 & is expected to grow at a CAGR of 10% from 2022-2028. The analysis has been segmented into Product (Instruments and Reagents & Kits); Sample (Blood, Urine, and Saliva); Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, and Others); Biomarker (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (CtDNA), Circulating Free DNA, And Others); Technique (Polymerase Chain Reaction and Next-Generation Sequencing); Region/Country.
Click here to view the Report Description & TOC- https://univdatos.com/report/liquid-biopsy-in-cancer-diagnostic-market/
The liquid biopsy in cancer diagnostic market report has been aggregated by collecting informative data on various dynamics such as market drivers, restraints, and opportunities. This innovative report makes use of several analyses to get a closer outlook on the liquid biopsy in cancer diagnostic market. The liquid biopsy in cancer diagnostic market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth. Furthermore, this statistical market research repository examines and estimates the liquid biopsy in cancer diagnostic market at the global and regional levels.
Request for Sample Pages - https://univdatos.com/get-a-free-sample-form-php/?product_id=36498
Key Market Drivers
The introduction of liquid biopsy tests has significantly transformed the diagnosis of various cancers, and offering ase in tumor sampling, continuous monitoring by repeated sampling, devising personalized therapeutic regimens, and screening for therapeutic resistance. The promising response has initiated further research and development in this domain, thus propelling market growth. For instance, in July 2022, UCF researchers designed a novel liquid biopsy technique that helps in the detection of metastatic cancer in the blood, which in the future could help identify cancer earlier and give patients more treatment options. In addition to this, rapid product approvals by regulatory bodies are also boosting the growth of liquid biopsy in cancer diagnostic market. For instance, in August 2022, Predicine launched its CE-marked PredicineCARE for genomic profiling in blood and urine in Europe. The cell free DNA (cfDNA) assay is a targeted next-generation sequencing (NGS) assay for the detection of single nucleotide variants, insertions and deletions, DNA re-arrangements, and copy number variations in patients diagnosed with cancer.
COVID-19 Impact
The COVID-19 pandemic has had a significant impact on the liquid biopsy in cancer diagnostic test market. The COVID-19 global pandemic has restricted the growth rate of the liquid biopsy market to some extent during 2020-2021. However, many countries have taken strict measures to combat the coronavirus, such as mass vaccination program, social distancing, use of masks, etc. Moreover, Cornell University researchers have also designed liquid biopsy that detects and quantifies injury to internal organs from coronavirus disease 2019 (COVID-19). The test profiles epigenetic changes in circulating cell-free DNA (cfDNA)—small fragments of genetic material from dead cells, including those killed off by infection or immune-related injury.
· By product, the market is bifurcated into instruments and reagents & kits. The reagents & kits segment held significant share of the market in 2021.
· By sample, the market is categorized into blood, urine, and saliva. The urine category is anticipated to grow with a high CAGR during the forecast period owing to several advantages including non-invasiveness, early detection, high DNA yield, and ability to identify genetic disorders.
· On the basis of cancer, the market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, and others. The lung cancer segment held the dominant share of the market in 2021 due to the growing number of patients with lung cancer.
· On the basis of biomarker, the market is segmented into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating free DNA, and others. Circulating tumor DNA held the dominant share in the market in 2021.
· Based on technique, the market is bifurcated into polymerase chain reaction and next-generation sequencing. The next generation sequencing category is anticipated to grow with significant CAGR during the forecast period as it is able to detect several mutations which is critical for the development of tumor.
Have a Look at the Chapters - https://univdatos.com/report/liquid-biopsy-in-cancer-diagnostic-market/
Liquid Biopsy In Cancer Diagnostic Market Geographical Segmentation Includes:
· North America (U.S., Canada, and the Rest of North America)
· Europe (Germany, UK, Spain, France, Italy, Rest of Europe)
· Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific)
· Rest of the World
North America held a dominant share in the market in 2021 owing to increased adoption of cancer therapy and rise in the incidence of cancer in U.S. According to the Globocan 2020 report, an estimated 2,281,658 new cancer cases were diagnosed in the U..S in 2020, with nearly 612,390 deaths. Apart from this, the presence of major key players, rising investments by pharmaceutical companies, and favorable government regulatory policies are also propelling regional market growth. For instance, in December 2022, U.S. FDA granted approval to Agilent Technologies Inc.’s Agilent Resolution ctDx FIRST as a companion diagnostic (CDx) to identify advanced non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations who may benefit from treatment with Krazatitm (adagrasib).
Competitive Landscape
The degree of competition among prominent global companies has been elaborated by analyzing several leading key players operating worldwide. The specialist team of research analysts sheds light on various traits such as global market competition, market share, most recent industry advancements, innovative product launches, partnerships, mergers, or acquisitions by leading companies in the liquid biopsy in cancer diagnostic market. The major players have been analyzed by using research methodologies such as Porter’s Five Forces Analysis for getting insight views on global competition.
Recent Developments:
· In November 2022, Exact Sciences launched new venture, Baltimore which has raised USD 56 million in funding led by New York-based investment firm Catalio Capital Management for the development of new liquid biopsy test for the detection of cancer.
· In October 2021, Caris Life Science entered into collaboration with ESSA Pharma to evaluate patient blood samples to assess genetic profiles utilizing Caris' Whole Transcriptome Sequencing (WTS) and Whole Exome Sequencing (WES) platform. ESSA will utilize these liquid biopsies, including longitudinal data from serial samples, to better characterize the tumor biological profiles of patients in the ongoing monotherapy clinical trial of EPI-7386 in mCRPC patients.
Key questions resolved through this analytical market research report include:
• What are the latest trends, new patterns, and technological advancements in the liquid biopsy in cancer diagnostic market?
• Which factors are influencing the liquid biopsy in cancer diagnostic market over the forecast period?
• What are the global challenges, threats, and risks in the liquid biopsy in cancer diagnostic market?
• Which factors are propelling and restraining the liquid biopsy in cancer diagnostic market?
• What are the demanding global regions of the liquid biopsy in cancer diagnostic market?
• What will be the global market size in the upcoming years?
• What are the crucial market acquisition strategies and policies applied by global companies?
• What are the descriptive profiles of key companies along with their SWOT analysis?
We understand the requirement of different businesses, regions, and countries, we offer customized reports as per your requirements of business nature and geography. Please let us know If you have any custom needs.